Laparoscopic RFA vs Myomectomy: Which Has Lower Failure?

Gynecologists frequently evaluate surgical strategies for symptomatic uterine leiomyomata. Currently, laparoscopic radiofrequency ablation serves as a uterine-sparing alternative to traditional surgery. However, comparative data regarding long-term reintervention rates remain essential for surgical counseling. Recent findings from the prospective ULTRA registry now provide critical comparative outcomes. Consequently, clinicians can better guide patients toward appropriate surgical selections.

Primary Findings on Laparoscopic Radiofrequency Ablation

The multicenter ULTRA trial followed women for two years after surgery. Specifically, investigators compared 231 patients undergoing ablation with 110 patients undergoing laparoscopic myomectomy. Women in the ablation cohort exhibited older age, higher gravidity, and higher body mass index. Even after multivariable adjustments, the ablation group demonstrated significantly higher treatment failure rates. Indeed, surgical reintervention occurred in 15.2% of ablation patients versus only 3.8% of myomectomy patients.

Furthermore, researchers tracked composite treatment failure within the two-year period. This composite metric combined secondary surgical intervention with persistent, lifestyle-limiting symptoms. In this category, 46.4% of ablation patients experienced composite failure compared to 25.5% of myomectomy patients. Therefore, patients receiving thermal ablation had more than threefold higher odds of composite failure.

Anatomic Predictors of Treatment Failure

Tumor anatomy significantly affected ablation success in this investigation. In particular, submucosal leiomyomata increased failure risks nearly threefold among ablation recipients. Similarly, lateral tumor locations substantially elevated failure odds in the ablation cohort. In contrast, tumor location did not predict failure among women receiving myomectomy. Consequently, anatomical mapping remains crucial prior to selecting an energy-based intervention.

These structural disparities likely reflect the physical limitations of thermal coagulative necrosis. Large or peripherally situated myomas often receive incomplete thermal coverage during tissue ablation. As a result, residual viable smooth muscle tissue may provoke recurrent menorrhagia or pelvic pressure. Conversely, laparoscopic excision completely removes the offending neoplasm from the uterine wall. Thus, myomectomy provides more durable symptom relief for complex anatomic distributions.

Clinical Takeaways for Indian Gynecologists

Uterine leiomyomas represent an exceedingly common indication for gynecological surgery in India. While patients increasingly seek minimally invasive interventions, clinicians must carefully communicate durability profiles. For instance, counseling should emphasize that ablation carries a higher reoperation risk. In addition, younger women and those with submucosal fibroids achieve superior durability with myomectomy. Therefore, surgeons should reserve thermal ablation for carefully selected candidates desiring rapid recovery.

Frequently Asked Questions

Q1: Why does laparoscopic radiofrequency ablation have higher failure rates than myomectomy?

Ablation induces coagulative necrosis rather than removing tissue directly. Consequently, untreated or incompletely treated leiomyoma cells can persist and produce recurrent symptoms.

Q2: Which leiomyoma locations carry the greatest failure risk with ablation?

Submucosal and lateral leiomyomata carry the greatest risk of failure after ablation. In contrast, tumor location does not significantly impair myomectomy outcomes.

Q3: What constitutes composite treatment failure in fibroid interventions?

Composite failure includes either receipt of a subsequent surgical intervention or continued patient-reported symptoms that impair health-related quality of life.

References

1. Brito KS et al. Treatment Failure After Laparoscopic Radiofrequency Ablation Compared With Myomectomy. Obstet Gynecol. 2026 Oct 13. doi: 10.1097/AOG.0000000000006444. PMID: 42868327.
2. Sendukas EA, Shields JK, Kho KA, et al. Combined Laparoscopic Radiofrequency Ablation and Laparoscopic Myomectomy: An Analysis of the ULTRA-Registry. JSLS. 2026;30(3):e2026.00048.
3. Jacoby VL, Schembri M, Varon S, et al. Effectiveness of Laparoscopic Radiofrequency Ablation of Uterine Leiomyomas Compared With Myomectomy on Symptoms and Health-Related Quality of Life. Obstet Gynecol. 2026;148(4):e1-e10.